One- versus three-month dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromes
EuroIntervention · 2024-05 · 20 (10) · e630-e642
DOI: 10.4244/eij-d-23-00658 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift EuroIntervention, 2024-05. Verfasst von Davide Cao und 29 weiteren Autor:innen. Beteiligte Einrichtung: Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Acute Coronary Syndrome, Platelet Aggregation Inhibitors, Hemorrhage. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: A short dual antiplatelet therapy (DAPT) duration has been proposed for patients at high bleeding risk (HBR) undergoing drug-eluting coronary stent (DES) implantation. Whether this strategy is safe and effective after a non-ST-segment elevation acute coronary syndrome (NSTE-ACS) remains uncertain. AIMS: We aimed to compare the impact of 1-month versus 3-month DAPT on clinical outcomes after DES implantation among HBR patients with or without NSTE-ACS. METHODS: This is a prespecified analysis from the XIENCE Short DAPT programme involving three prospective, international, single-arm studies evaluating the safety and efficacy of 1-month (XIENCE 28 USA and Global) or 3-month (XIENCE 90) DAPT among HBR patients after implantation of a cobalt-chromium everolimus-eluting stent. Ischaemic and bleeding outcomes associated with 1- versus 3-month DAPT were assessed according to clinical presentation using propensity score stratification. RESULTS: Of 3,364 HBR patients (1,392 on 1-month DAPT and 1,972 on 3-month DAPT), 1,164 (34.6%) underwent DES implantation for NSTE-ACS. At 12 months, the risk of the primary endpoint of death or myocardial infarction was similar between 1- and 3-month DAPT in patients with (hazard ratio [HR] 1.09, 95% confidence interval [CI]: 0.71-1.65) and without NSTE-ACS (HR 0.88, 95% CI: 0.63-1.23; p-interaction=0.34). The key secondary endpoint of Bleeding Academic Research Consortium (BARC) Type 2-5 bleeding was consistently reduced in both NSTE-ACS (HR 0.57, 95% CI: 0.37-0.88) and stable patients (HR 0.84, 95% CI: 0.61-1.15; p-interaction=0.15) with 1-month DAPT. CONCLUSIONS: Among HBR patients undergoing implantation of an everolimus-eluting stent, 1-month, compared to 3-month DAPT, was associated with similar ischaemic risk and reduced bleeding at 1 year, irrespective of clinical presentation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
- Heart Centre Hasselt, Hasselt, Belgium and University of Hasselt, Hasselt, Belgium.
- Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano, Switzerland.
- Bern University Hospital, Bern, Switzerland.
- University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USA.
Zitieren
APA
Cao, D., Vranckx, P., Valgimigli, M., Sartori, S., Angiolillo, D. J., Bangalore, S., Bhatt, D. L., Feng, Y., Ge, J., Hermiller, J., Makkar, R. R., Neumann, F. J., Saito, S., Picon, H., Toelg, R., Maksoud, A., Chehab, B. M., Choi, J. W., Campo, G., …, & Mehran, R. (2024). One- versus three-month dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromes. EuroIntervention, 20(10), e630-e642. https://doi.org/10.4244/eij-d-23-00658
Vancouver
Cao D, Vranckx P, Valgimigli M, Sartori S, Angiolillo DJ, Bangalore S, et al. One- versus three-month dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromes. EuroIntervention. 2024;20(10):e630-e642. doi:10.4244/eij-d-23-00658
BibTeX
@article{Cao2024,
author = {Cao, Davide and Vranckx, Pascal and Valgimigli, Marco and Sartori, Samantha and Angiolillo, Dominick J and Bangalore, Sripal and Bhatt, Deepak L and Feng, Yihan and Ge, Junbo and Hermiller, James and Makkar, Raj R and Neumann, Franz-Josef and Saito, Shigeru and Picon, Hector and Toelg, Ralph and Maksoud, Aziz and Chehab, Bassem M and Choi, James W and Campo, Gianluca and De la Torre Hernandez, José M and Krucoff, Mitchell W and Kunadian, Vijay and Sardella, Gennaro and Spirito, Alessandro and Thiele, Holger and Varenne, Olivier and Vogel, Birgit and Zhou, Yujie and Windecker, Stephan and Mehran, Roxana},
title = {One- versus three-month dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromes},
journal = {EuroIntervention},
year = {2024},
volume = {20},
number = {10},
pages = {e630--e642},
doi = {10.4244/eij-d-23-00658}
}
EUVIMED